


R⁴ is selected from alkyl or haloalkyl;

R⁵ is alkyl;

R⁶ is selected from Ar¹, (chromanyl)alkyl, (dihydrobenzodioxinyl)alkyl, or cyanocycloalkyl; and

Ar¹ is phenyl substituted with 0-5 substituents selected from cyano, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, (hydroxy)alkoxy, (alkoxy)alkoxy, phenoxy, benzyloxy, carboxy, phenyl, and cyanocycloalkyl;
or a pharmaceutically acceptable salt thereof.

10. A compound of Formula I



wherein:

R¹ is selected from hydrogen, alkyl, or cycloalkyl;

R² is selected from tetrahydroisoquinolinyl and is substituted with 1 R⁶ substituent and also with 0-3 halo or alkyl substituents;

R³ is selected from azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;

R⁴ is selected from alkyl or haloalkyl;

R⁵ is alkyl;

R⁶ is selected from Ar¹, (Ar¹)alkyl, (chromanyl)alkyl, cyanocycloalkyl or (dihydrobenzodioxinyl)alkyl; and

Ar¹ is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, (hydroxy)alkoxy, (alkoxy)alkoxy, phenoxy, benzyloxy, carboxy, phenyl, and cyanocycloalkyl;
or a pharmaceutically acceptable salt thereof.

11. A composition for use in treating HIV infection comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

12. The composition of claim 11 further comprising a therapeutically effective amount at least one other agent used for treatment of AIDS or HIV infection selected from nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors, and a pharmaceutically acceptable carrier.
13. The composition of claim 12 wherein the other agent is dolutegravir.
14. Use of a compound of claim 1, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating HIV infection, wherein a patient in need thereof is to be administered with a therapeutically effective amount of said compound, or the pharmaceutically acceptable salt thereof.
15. The use of claim 14, wherein the patient is to be further administered with a therapeutically effective amount of at least one other agent used for treatment of AIDS or HIV infection selected from nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.
16. The use of claim 15 wherein the other agent is dolutegravir.
17. The use of claim 15 wherein the other agent is to be administered to the patient prior to, simultaneously with, or subsequently to the compound of claim 1.